Fluids exclusively enteral from day one in premature infants

ISRCTN ISRCTN89654042
DOI https://doi.org/10.1186/ISRCTN89654042
Secondary identifying numbers DHRD/2018/116
Submission date
10/09/2019
Registration date
23/09/2019
Last edited
11/09/2024
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Neonatal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Around 8% of UK babies are born premature at birth and 12% of these are born between 30 and 33 weeks. Currently, most preterm babies are fed through a drip into their veins (intravenous) and given small amounts of milk by a small tube into their stomach, slowly increasing until they are fully milk fed. Doctors are wary of feeding premature babies with full milk straight after birth due to a potentially life-threatening gut condition called necrotising enterocolitis (NEC).

Evidence suggests that in premature babies who aren't too poorly, larger milk feeds can be successfully given within 48 hours of birth without increasing the risk of NEC and death, and could reduce the risk of severe infection.

We want to know if feeding babies on with milk only from the first day of life, avoiding giving them fluids through a drip (IV), can reduce infections, reduce the number of days in hospital and therefore reduce the overall costs to parents and to the NHS.

Who can participate?
Infants born at 30 - 33 weeks gestation

What does the study involve?
We will compare two different groups: the 'full milk' group will be given milk to provide all their fluid needs from the first day of life and increased over a few days unless they are struggling with this (e.g. if it makes them very sick). In the 'gradual milk' group, babies will be initially fed through their veins, increasing milk feeds slowly and reducing IV fluids until they are fully milk fed, which is current practice.

What are the possible benefits and risks of participating?
We do not know if taking part in the study will benefit parents or babies directly, but by doing this study we are hoping to find the best way of feeding preterm babies which may help to guide the care of premature babies in the future.

If a baby is in the full milk group, they will be given milk from the first day. This amount of milk may be difficult for babies to tolerate and they may vomit and/or develop bloating. If this happens the doctors and nurses caring for the babies will decide what is best for them and may give smaller amounts of milk more frequently or reduce the amount of milk. There may be benefits from full milk from day 1, such as reducing infections and the need for drips associated with IV feeding in the gradual milk group.

Where is the study run from?
Nottingham Clinical Trials Unit (UK)

When is the study starting and how long is it expected to run for?
October 2019 to September 2027

Who is funding the study?
National Institute for Health Research (NIHR) (UK)

Who is the main contact?
Garry Meakin
feed1@nottingham.ac.uk

Study website

Contact information

Mr Garry Meakin
Public

Nottingham Clinical Trials Unit
Building 42 University Park
Nottingham
NG7 2RD
United Kingdom

ORCiD logoORCID ID 0000-0001-8593-3421
Phone +44 (0) 1158231587
Email feed1@nottingham.ac.uk

Study information

Study designMulti-centre open parallel randomised controlled superiority trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet ISRCTN89654042_PIS_V1.1_16Aug19.pdf
Scientific titleA randomised controlled trial of full milk feeds versus intravenous nutrition with gradual feeding for preterm infants (30-33 weeks gestational age)
Study acronymFEED1
Study hypothesisTo investigate whether, in infants born at 30+0 to 32+6 weeks+days (inclusive) gestation, full milk feeds initiated in the first 24 hours of life reduce the length of hospital stay in comparison to IV fluids with gradual milk feeding
Ethics approval(s)Approved 13/09/2019, East Midlands Derby REC (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS; +44 (0) 2071048036; NRESCommittee.eastmidlands-derby@nhs.net), ref: 19/EM/0258.
ConditionNeonatal nutrition
InterventionMothers will be randomised in a 1:1 ratio, for their infants to receive either:
1. Intervention – infant(s) started on full milk feeds (a minimum of 60ml per kg of the baby’s weight each day) from day 1.
2. Control – infant(s) started on a small amount of milk (maximum of 30ml per kg of the baby’s weight each day) along with intravenous fluids/nutrition as per usual care.

Milk will then be gradually increased in each arm, as per the local hospitals usual practice, until they reach full milk feeds (defined as 140ml per kg of the baby’s weight each day). Routine data will be collected until the infant is discharged from hospital. A further follow-up will be conducted via a questionnaire to be completed by the mother once the infant reaches 6 weeks corrected age.

Intervention: full milk feeding from day one

Comparator: parenteral nutrition/intravenous fluids with gradual milk feeding as per usual local practice

Mothers will be identified at the antenatal clinic or within 3 hours of early arrival. The groups will be decided at random by a computer giving each baby an equal chance of being in either group.

The selection of the outcome measures has been guided by the Core Outcomes in Neonatology (COIN) core outcome set, developed by a steering committee comprised of parents and former patients, healthcare professionals and researchers.

A subsequent funding application will be submitted to extend the scope of this trial to follow-up infants at 2 years of corrected gestational age. We intend to compare data on survival to 2 years of age and neurodevelopmental impairment including the remaining COIN outcomes (general gross motor ability, general cognitive ability, visual impairment or blindness, hearing impairment or deafness).
Intervention typeOther
Primary outcome measureLength of hospital stay
Secondary outcome measures1. Survival to hospital discharge
2. Survival to 6 weeks corrected gestational age (i.e. term gestation + 6 weeks)
3. Incidence of microbiologically-confirmed (positive blood/cerebrospinal fluid [CSF] culture) or clinically suspected (defined by diagnostic criteria) late-onset sepsis until hospital discharge
4. Necrotising enterocolitis (Bell’s stage 2 or 3) until hospital discharge
5. Time taken to maintain full milk feeding (defined as at least 140 ml/kg/d for three consecutive days)
6. Time to regain birth weight
7. Growth (z scores for gestational age at hospital discharge (as per UK-NICM growth charts))
7.1 Weight in kg
7.2 Length in cm
7.3 Head circumference in cm
8. Breastfeeding at hospital discharge
9. Breast milk fed at hospital discharge
10. Number of days of peripheral cannula until full milk feeding (defined as at least 140 ml/kg/d for three consecutive days) achieved
11. Number of IV cannulae inserted until full milk feeding (defined as at least 140 ml/kg/d for three consecutive days) achieved
12. Number of days of parenteral nutrition, until hospital discharge
13. Number of central venous lines inserted (including umbilical and percutaneous or surgically inserted venous lines) until hospital discharge
14. Number of central line days until hospital discharge
15. Time until objective discharge criteria are met
16. Hospital visits (including day care and overnight admissions) up to 6 weeks of corrected age (i.e. term gestation + 6 weeks)
17. Breast feeding at 6 weeks of corrected age (i.e. term gestation + 6 weeks)
18. Breast milk fed at 6 weeks of corrected age (i.e. term gestation + 6 weeks)
19. Parental satisfaction and wellbeing at 6 weeks of corrected age (i.e. term gestation + 6 weeks), using the Preterm Birth Experience and Satisfaction Scale (p-BESS) questionnaire
Overall study start date01/04/2019
Overall study end date30/09/2027

Eligibility

Participant type(s)Patient
Age groupNeonate
SexBoth
Target number of participants2088
Total final enrolment2088
Participant inclusion criteria1. Infant born at 30 weeks + 0 days to 32 weeks + 6 days gestation, inclusive
2. Infant <3 hours (180 minutes) old (since recorded time of birth)

(Infants requiring respiratory support (such as via continuous positive airway pressure) or other supportive treatments will be included in the study if the attending clinician is in equipoise about the infant being randomised to either the “full milk” or the “gradual milk” arm. Similarly, well infants should only be included if the attending clinician is in equipoise about the best feeding regime and the infant being randomised to either “full milk” or “gradual milk” groups.)
Participant exclusion criteria1. Infant with known congenital abnormalities of the gastrointestinal tract or other congenital conditions that make enteral feeding unsafe
2. Infant who are small for gestational age (birth weight <10th centile) AND evidence of reversed end-diastolic flow on antenatal umbilical artery Doppler ultrasound*
3. Mother has participated in the trial during a previous pregnancy#

*Small for gestational age infants with antenatal Doppler ultrasound scan showing absent umbilical artery flow or whose mother’s did not have antenatal umbilical Doppler ultrasound may be eligible for the trial if they meet the other inclusion criteria.

#The trial will recruit over 36 months. It is possible that the mother of an infant(s) who has already participated in the trial has another pregnancy in this duration. In such circumstances, the infant(s) born in subsequent pregnancies will be excluded to avoid bias due to the experience of previous participation.
Recruitment start date01/10/2019
Recruitment end date14/07/2024

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Nottingham Clinical Trials Unit
Building 42
Room A17
University Park
Nottingham
NG7 2RD
United Kingdom

Sponsor information

University Hospitals of Derby and Burton NHS Foundation Trust
Hospital/treatment centre

Research and Development,. Royal Derby Hospital
Derby
DE22 3DT
England
United Kingdom

Phone 01332724710
Email dhft.sponsor@nhs.net
Website https://www.uhdb.nhs.uk/

Funders

Funder type

Not defined

National Institute for Health Research
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date30/12/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.
IPD sharing planThe datasets analysed during the current study will be available upon request from the NCTU (ctu@nottingham.ac.uk), a minimum of 6 months after publication of the main results paper. Access to the data will be subject to review of a data sharing and use request by a committee including the CI and sponsor, and will only be granted upon receipt of a data sharing and use agreement. Any data shared will be pseudoanonymised which may impact on the reproducilbilty of published analyses.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version V1.1 16/08/2019 23/09/2019 No Yes
Protocol article 20/01/2022 24/01/2022 Yes No
HRA research summary 28/06/2023 No No

Additional files

ISRCTN89654042_PIS_V1.1_16Aug19.pdf
Uploaded 23/09/2019

Editorial Notes

11/09/2024: The following changes were made:
1. The recruitment end date was changed from 30/09/2024 to 14/07/2024.
2. The intention to publish date was changed from 30/09/2027 to 30/12/2025.
3. The total final enrolment number was added.
07/02/2023: The intention to publish date was changed from 31/07/2023 to 30/09/2027.
02/02/2023: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/09/2022 to 30/09/2024.
2. The overall trial end date was changed from 31/01/2023 to 30/09/2027.
3. Trial website added.
04/01/2023: Trial status confirmed.
24/01/2022: Publication reference added.
21/04/2021: Recruitment has resumed.
20/04/2020: Due to current public health guidance, recruitment for this study has been paused.
23/09/2019: Trial's existence confirmed by the NIHR. The participant information sheet has been uploaded.